LEADER 03674oam  2200577   450 
001 9910298354103321
005 20190911103515.0
010   $a1-4899-8002-4
024 7 $a10.1007/978-1-4899-8002-1
035   $a(OCoLC)868918491
035   $a(MiFhGG)GVRL6YWD
035   $a(EXLCZ)993710000000073699
100   $a20131030d2014      uy             0
101 0 $aeng
135   $aurun|---uuuua
181   $ctxt
182   $cc
183   $acr
200 10$aObesity and breast cancer $ethe role of dysregulated estrogen metabolism /$fKristy A. Brown, Evan R. Simpson
205   $a1st ed. 2014.
210  1$aNew York :$cSpringer,$d2014.
215   $a1 online resource (ix, 56 pages) $cillustrations (chiefly color)
225 1 $aSpringerBriefs in Cancer Research,$x2194-1173
300   $aDescription based upon print version of record.
311   $a1-4899-8001-6 
320   $aIncludes bibliographical references.
327   $aIntroduction -- Estrogens, adiposity and the menopause -- The link between obesity and breast cancer: Epidemiological evidence -- Adipose-derived and obesity-related factors and breast cancer -- Estrogen biosynthesis -- Therapies aimed at breaking the linkage between obesity and breast cancer -- Conclusions.
330   $aObesity is a risk factor for breast cancer in older women. A number of adipose-derived and obesity-related factors have been shown to affect tumour cell growth. These include adipokines, insulin, IGF-1 and oestrogens. The majority of obesity-related postmenopausal breast cancers are oestrogen-dependent. Since the ovaries no longer produce oestrogens after menopause, and that circulating levels are negligible, it is evident that it is the oestrogens produced locally within the breast adipose that are responsible for the increased growth of breast cancer cells. Aromatase is the enzyme that converts androgens into oestrogens and its regulation is dependent on the activity of a number of tissue-specific promoters. Targeting oestrogen biosynthesis in obesity may be useful for the prevention of breast cancer. Aromatase inhibitors are efficacious at treating postmenopausal breast cancer and recent studies suggest that they may also be useful in the prevention setting. However, these compounds inhibit the catalytic activity of aromatase and as a consequence lead to a number of undesirable side-effects, including arthralgia and possible cognitive defects due to inhibition of aromatase in the bone and brain, respectively. Novel therapies, such as those employed to treat obesity-associated disease, including anti-diabetics, may prove successful at inhibiting aromatase specifically within the breast. This SpringerBrief will explore all of these issues in depth and the authors are in a unique position to write about this topic, having extensive experience in the field of aromatase research.
410  0$aSpringerBriefs in cancer research.
606   $aEnzymes
606   $aBreast$xCancer$xEtiology
606   $aBreast$xCancer$xRisk factors
606   $aMetabolism$xDisorders
606   $aObesity
606   $aOncology
615  0$aEnzymes.
615  0$aBreast$xCancer$xEtiology.
615  0$aBreast$xCancer$xRisk factors.
615  0$aMetabolism$xDisorders.
615  0$aObesity.
615  0$aOncology.
676   $a572.6
676   $a616.99/4071
700   $aBrown$b Kristy A$4aut$4http://id.loc.gov/vocabulary/relators/aut$01059858
702   $aSimpson$b E. R$g(Evan R.),
801  0$bMiFhGG
801  1$bMiFhGG
906   $aBOOK
912   $a9910298354103321
996   $aObesity and Breast Cancer$92508876
997   $aUNINA